114 related articles for article (PubMed ID: 34982424)
21. HMGN5 promotes invasion and migration of colorectal cancer through activating FGF/FGFR pathway.
Zhu GJ; Liu F; Xu YG; Zhao CX; Zhao JG; Sun C
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1330-1338. PubMed ID: 33629303
[TBL] [Abstract][Full Text] [Related]
22. LncRNA LINP1 promotes malignant progression of pancreatic cancer by adsorbing microRNA-491-3p.
Chen AY; Zhang K; Liu GQ
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9315-9324. PubMed ID: 33015772
[TBL] [Abstract][Full Text] [Related]
23. MiRNA-199 inhibits malignant progression of lung cancer through mediating RGS17.
Su WZ; Ren LF
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3390-3400. PubMed ID: 31081094
[TBL] [Abstract][Full Text] [Related]
24. Low expression of long non-coding RNA GAS5 is associated with poor prognosis of patients with thyroid cancer.
Guo LJ; Zhang S; Gao B; Jiang Y; Zhang XH; Tian WG; Hao S; Zhao JJ; Zhang G; Hu CY; Yan J; Luo DL
Exp Mol Pathol; 2017 Jun; 102(3):500-504. PubMed ID: 28506768
[TBL] [Abstract][Full Text] [Related]
25. LncRNA TNRC6C-AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR-129-5p.
Hou S; Lin Q; Guan F; Lin C
J Cell Biochem; 2018 Nov; 119(10):8304-8316. PubMed ID: 29893424
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a.
Xu L; Hou TJ; Yang P
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6505-6515. PubMed ID: 31378890
[TBL] [Abstract][Full Text] [Related]
27. Long intergenic noncoding RNA 00844 promotes apoptosis and represses proliferation of prostate cancer cells through upregulating GSTP1 by recruiting EBF1.
Qiu K; Zheng Z; Huang Y
J Cell Physiol; 2020 Nov; 235(11):8472-8485. PubMed ID: 32329523
[TBL] [Abstract][Full Text] [Related]
28. Circ-DONSON promotes malignant progression of glioma through modulating FOXO3.
Zou Z; Dong YS; Liu JM; Zhao ZH; Li G; Liu DD
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):749-757. PubMed ID: 32016978
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of LINC00261 inhibits non-small cell lung cancer cells progression by interacting with miR-522-3p and suppressing Wnt signaling.
Shi J; Ma H; Wang H; Zhu W; Jiang S; Dou R; Yan B
J Cell Biochem; 2019 Oct; 120(10):18378-18387. PubMed ID: 31190356
[TBL] [Abstract][Full Text] [Related]
30. IGF2BP2 knockdown suppresses thyroid cancer progression by reducing the expression of long non-coding RNA HAGLR.
Dong L; Geng Z; Liu Z; Tao M; Pan M; Lu X
Pathol Res Pract; 2021 Sep; 225():153550. PubMed ID: 34340128
[TBL] [Abstract][Full Text] [Related]
31. [The expression of long non-coding RNA LINC00261 in laryngeal carcinoma tissue and their clinical significance].
Zhang CM; Gao W; Wu YY; Zhao QL; Chen B; Liu QQ; Li WY; Wen SX; Wang BQ
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 31(1):68-71. PubMed ID: 29774690
[No Abstract] [Full Text] [Related]
32. LncRNA MORT negatively regulates FGF1 to suppress malignant progression of breast cancer.
Yang Q; Yang D; Zhu HB; Li P; Wu XP; Tan YR
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6179-6186. PubMed ID: 34730198
[TBL] [Abstract][Full Text] [Related]
33. LncSNHG16 promotes proliferation and migration of osteosarcoma cells by targeting microRNA-146a-5p.
Zheng SN; Ge DW; Tang J; Yang J; Yan JW; Qiu JJ; Yin ZW; Ni Y; Zhao L; Chen X; Yang L
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):96-104. PubMed ID: 30657551
[TBL] [Abstract][Full Text] [Related]
34. CSN6 promotes malignant progression of oral squamous cell carcinoma by down-regulating TIMP-2.
Gao WY; Yang G; Wang J; He JM; Wang P
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5419-5428. PubMed ID: 32495877
[TBL] [Abstract][Full Text] [Related]
35. Decreased expression of long non-coding RNA LINC00261 is a prognostic marker for patients with non-small cell lung cancer: a preliminary study.
Liu Y; Xiao N; Xu SF
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5691-5695. PubMed ID: 29272004
[TBL] [Abstract][Full Text] [Related]
36. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
[TBL] [Abstract][Full Text] [Related]
37. LINC00261 inhibits progression of pancreatic cancer by down-regulating miR-23a-3p.
Wang X; Gao X; Tian J; Zhang R; Qiao Y; Hua X; Shi G
Arch Biochem Biophys; 2020 Aug; 689():108469. PubMed ID: 32590069
[TBL] [Abstract][Full Text] [Related]
38. LncRNA UNC5B-AS1 promotes malignant progression of prostate cancer by competitive binding to caspase-9.
Tan SF; Ni JX; Xiong H
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2271-2280. PubMed ID: 32196578
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of long non‑coding RNA CCAT2 suppresses the progression of thyroid cancer by inhibiting the Wnt/β‑catenin pathway.
Xin S; Ye X
Int J Mol Med; 2020 Dec; 46(6):2047-2056. PubMed ID: 33125134
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA LINC00261 inhibits cell growth and migration in endometriosis.
Sha L; Huang L; Luo X; Bao J; Gao L; Pan Q; Guo M; Zheng F; Wang H
J Obstet Gynaecol Res; 2017 Oct; 43(10):1563-1569. PubMed ID: 28707780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
